About Panflu Sinovac Panflu is an inactivated whole virus vaccine with adjuvant.

About Panflu Sinovac Panflu is an inactivated whole virus vaccine with adjuvant. Four antigen dosages levels were tested in the phase I clinical trial and all of them induces an immune response in the volunteers. The vaccine with 10ug antigen content demonstrated the best immunogenicity, with a sero-positive rate of 78, which exceeds the criteria established for the evaluation of vaccines by the Committee for Proprietary Medicinal Products of the European Union. May 2005.ternational Cooperation.

Researchers from MD Anderson Cancer Center say that the number of cancer patients need radiotherapy will increase 22 %, but the number of new, full-time radiation oncologists will increase just 2 %. – the shortage could severely affect patient care. Study data indicated groups are most likely to feel the? people people age 65 and over increase increase the need for radiation therapy see 38 %, and minorities who? Could you? See demand increase of 45 %.This has been previously shown that folic acid may forticifation Jekyll and Hyde characteristics, the protect some people, whereas to harm others. For example, trials have confirming that unmetabolised folic acid accelerates cognitive deterioration the elderly with low vitamin B12 status natural strains can be protected normal B12 status to cognitive impairment. The majority over-65s in Germany are low in B12 status.